1. Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study
- Author
-
Jean-François Rossi, Emmanuel Bonnet, Christel Castelli, Marion Velensek, Emma Wisniewski, Sophie Heraud, Rania Boustany, Céleste David, Jérôme Dinet, Roland Sicard, Jean-Pierre Daures, Marion Bonifacy, Lysiane Mousset, and Emmanuel Goffart
- Subjects
COVID-19 ,serological follow-up ,hematological malignancies ,Medicine - Abstract
Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was p < 0.001), particularly for patients receiving rituximab. Patients with gammaglobulin levels < 5 g/L had reduced seroconversion compared to higher levels (p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs.
- Published
- 2023
- Full Text
- View/download PDF